.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XA53_TositumomabIodine131iTos.TositumomabIodine131iTos .Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XA53_TositumomabIodine131iTos.TositumomabIodine131iTos| name: | TositumomabIodine131iTositumomab | |
| ATC code: | V10XA53 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 450 | mg |
| volume of distribution: | 4.6 | L |
| clearance: | 0.049 | L/h |
| other parameters in model implementation | ||
Tositumomab/iodine (131I) tositumomab is a radiolabeled monoclonal antibody formerly used for the treatment of rituximab-refractory, CD20-positive, follicular non-Hodgkin's lymphoma. It combines the murine anti-CD20 IgG2a monoclonal antibody (tositumomab) with radioactive iodine-131 to target malignant B lymphocytes. The drug has been withdrawn from the market and is no longer approved for use.
Pharmacokinetic parameters in adult patients with relapsed or refractory non-Hodgkin's lymphoma; typical values in adults from various clinical reports.